Taurochenodeoxycholic acid reduces astrocytic neuroinflammation and alleviates experimental autoimmune encephalomyelitis in mice
The rates of newly diagnosed Type 1 and Type 2 diabetes cases are seen increasing among the youth in Europe
initial US approval 2022, paediatric T2D label updateTier 1 primary [3]NICE TA924: tirzepatide for treating type 2 diabetes (published 25 October 2023, updated 1 September 2025)Tier 1 primary [4]NICE TA1026: tirzepatide for managing overweight and obesity (published 23 December 2024, updated 1 September 2025)Tier 1 primary [5]Jastreboff et al
One way it does that is by supporting T cells, a type of white blood cell that attacks foreign invaders and protects you from infection (3)
Disruption of SUMOylation has been implicated in AD, HD and PD, where it contributes to protein aggregation, synaptic dysfunction, and neuronal vulnerability